Dyne Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Dyne Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- DYN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818794
Board of directors
-
Carlo Incerti · DirectorSince 2023
-
Catherine Stehman-Breen · DirectorSince 2023
-
David Charles Lubner · DirectorSince 2023
-
Dirk Kersten · DirectorSince 2023
-
Edward Hurwitz · DirectorSince 2023
-
Jason P. Rhodes · DirectorSince 2023
-
John Cox · Director · CEO & PresidentSince 2024
-
Joshua T. Brumm · Director · CEO & PresidentSince 2023
Chief executives
John Cox
· CEO & President
Since March 2024
Joshua T. Brumm
· CEO & President
Until March 2024
· Former
Board connections
4 of this board's directors also sit on 4 other boards.
- via David Charles Lubner and Joshua T. Brumm
- via Edward Hurwitz
- via Catherine Stehman-Breen
- via David Charles Lubner
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2025 | Friedl-Naderer Johanna Officer (Chief Commercial Officer) | Open-market sale | −143 | $12.12 | $1,733 |
| Mar 11, 2025 | Scalzo Richard William Officer (SVP, Head of Finance & Admin.) | Open-market sale | −1,343 | $11.38 | $15,283 |
| Mar 11, 2025 | Beskrovnaya Oxana Officer (Chief Scientific Officer) | Open-market sale | −2,153 | $11.38 | $24,501 |
| Mar 5, 2025 | Kerr Douglas Officer (Chief Medical Officer) | Open-market sale | −1,343 | $11.83 | $15,888 |
| Mar 5, 2025 | John Cox Director, Officer (CEO & President) | Open-market sale | −4,061 | $11.83 | $48,042 |
| Mar 5, 2025 | Scalzo Richard William Officer (SVP, Head of Finance & Admin.) | Open-market sale | −917 | $11.83 | $10,848 |
| Mar 5, 2025 | Beskrovnaya Oxana Officer (Chief Scientific Officer) | Open-market sale | −1,094 | $11.83 | $12,942 |
| Feb 18, 2025 | Beskrovnaya Oxana Officer (Chief Scientific Officer) | Open-market sale | −2,598 | $13.95 | $36,242 |
| Feb 18, 2025 | Scalzo Richard William Officer (SVP, Head of Finance & Admin.) | Open-market sale | −2,488 | $13.95 | $34,708 |
| Jan 27, 2025 | Jason P. Rhodes Director | Grant or award | +1,111,111 | $13.50 | $14,999,999 |
| Dec 11, 2024 | Beskrovnaya Oxana Officer (Chief Scientific Officer) | Open-market sale | −2,334 | $28.12 | $65,632 |
| Dec 11, 2024 | Scalzo Richard William Officer (SVP, Head of Finance & Admin.) | Open-market sale | −1,455 | $28.12 | $40,915 |
| Dec 9, 2024 | Dirk Kersten Director | Open-market sale | −34,437 | $29.18 | $1,004,872 |
| Dec 6, 2024 | Dirk Kersten Director | Open-market sale | −101,675 | $29.34 | $2,983,145 |
| Dec 5, 2024 | Dirk Kersten Director | Open-market sale | −3,806 | $29.05 | $110,564 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.